Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


NeuroNova AB

Division of Newron Pharmaceuticals SPA

Latest From NeuroNova AB

Safinamide's MOTION could help Newron/Zambon SETTLE on PD market

Further to a pledge to expedite global filings for the Parkinson's disease (PD) compound safinamide, Newron Pharmaceuticals and its partner Zambon say regulatory submissions are expected in the US and EU in the fourth quarter, for the use of the drug both an add-on therapy to dopamine agonist therapy in patients with early PD and as an add-on to levodopa therapy in patients with advanced PD.


DEALS ROUND-UP: M&A and partnering 1-28 December

As companies flurried to clinch deals by the end of the year, a number of significant agreements were signed or completed last December.

Metabolic Disorders Infectious Diseases

Newron gets its way with NeuroNova at last

Newron Pharmaceuticals' management can breathe a sigh of relief: its shareholders have approved its plans to acquire NeuroNova. The Italian firm has announced that it received unanimous approval for revised proposals to acquire the Swedish biotech company at its shareholder meeting (where just over 40% of the shares were represented).

Neurology Japan

Zambon scuppers Newron ambitions

No one would have blamed Rolf Stahel, a Swiss national chairman of Newron, from recalling the English phrase "With friends like this who needs enemies" as Zambon, the company's major pharma partner, voted against plans by the Italian CNS company to acquire Swedish biotech company NeuroNova. Newron's management had hoped shareholders would support its ambition to acquire the Swedish company's pipeline and cash at an emergency general meeting,

See All

Company Information

  • Industry
  • Biotechnology
    • Large Molecule
  • Pharmaceuticals
  • Therapeutic Areas
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • Europe
      • Western Europe
        • Scandinavia
          • Sweden
  • Parent & Subsidiaries
  • Newron Pharmaceuticals SPA
  • Senior Management
  • Ulf Ljungberg, PhD, Pres. & CEO
    Henrik Resmark, CFO
    Anders Haegerstrand, MD, PhD, CSO
  • Contact Info
  • NeuroNova AB
    Phone: (46) (0)8 786 0900
    Fiskartorpsvägen 15 A-D
    Stockholm, SE-114 33